Expertise in
16
conditions

Dr. Alvaro F. Restrepo

Texas Oncology PA
Mcallen, TX
Expertise in
16
conditions
Specialties:Oncology | Hematology Oncology
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
OverviewInsuranceLocationsClinical Research

Overview

Alvaro Restrepo is an Oncologist and a Hematologist Oncology provider in Mcallen, Texas. Dr. Restrepo is highly rated in 16 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Paget Disease of the Breast, Colorectal Cancer, and Adult Soft Tissue Sarcoma. Dr. Restrepo is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
South Texas Health System
Rio Grande Regional Hospital
Doctors Hosptal At Renaissance
Mission Regional Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Friday Health
  •  Oscar
  •  UnitedHealthcare
  •  Humana

Locations

TEXAS ONCOLOGY PA
1901 S 2nd St, Mcallen, TX 78503
956-687-5150

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
Breast Cancer Index (BCI) Registry
Breast Cancer Index (BCI) Registry
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Diagnostic test
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Active_not_recruiting
Publish Date: September 13, 2023
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Enrollment Status: Terminated
Publish Date: March 24, 2021
Intervention Type: Drug
Study Drug: AVID100
Study Phase: Phase 1/Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

5 Total Publications

Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens.
Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens.
Journal: Breast cancer research and treatment
Published: May 19, 2023
Similar Doctors
Expertise in
25
conditions
Dr. Eugenio G. Galindo
Hematology Oncology | Hematology | Oncology
Expertise in
25
conditions
Dr. Eugenio G. Galindo
Hematology Oncology | Hematology | Oncology

Mcallen Oncology PA

Mcallen, TX 
 (6.1 mi)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Eugenio Galindo is a Hematologist Oncology specialist and a Hematologist in Mcallen, Texas. Dr. Galindo is highly rated in 25 conditions, according to our data. His top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Testicular Yolk Sac Tumor. Dr. Galindo is currently accepting new patients.

Expertise in
17
conditions
Dr. Suresh Ratnam
Oncology | Hematology Oncology
Expertise in
17
conditions
Dr. Suresh Ratnam
Oncology | Hematology Oncology

Texas Oncology PA

1901 S 2nd St, 
Mcallen, TX 
956-687-5150
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Suresh Ratnam is an Oncologist and a Hematologist Oncology provider in Mcallen, Texas. Dr. Ratnam is highly rated in 17 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Familial Prostate Cancer, and Prostate Cancer. Dr. Ratnam is currently accepting new patients.

Expertise in
11
conditions
Dr. Habib M. Ghaddar
Hematology Oncology | Oncology | Palliative Medicine
Expertise in
11
conditions
Dr. Habib M. Ghaddar
Hematology Oncology | Oncology | Palliative Medicine

Texas Oncology PA

1901 S Col Rowe Blvd, 
Mcallen, TX 
 (0.1 mi)
956-687-5150
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Habib Ghaddar is a Hematologist Oncology specialist and an Oncologist in Mcallen, Texas. Dr. Ghaddar is highly rated in 11 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, and Thymic Epithelial Tumor. Dr. Ghaddar is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile